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Introduction. Cardiovascular related diseases are the major cause of mortality in the developed 
countries. Intensive biological studies were devoted to the blood coagulation cascade in order to find the 
key enzymes responsible for the formation of the blood clots. Currently, treatment of strokes or 
infarctions caused by thromboembolism of vessels is carried out using thrombolytic therapy or by 
anticoagulant drugs.  
Factor X is the calcium-binding, gamma carboxyglutamyl(Gla)-containing, vitamin K dependent 
glycoprotein [1, p. 241-280]. The activity of Factor Xa is dependent on its inclusion in the 
prothrombinase complex. The prothrombinase complex converts the prothrombin into the active 
procoagulant thrombin. It is therefore clear that Factor Xa catalyzes the pre-final step in the blood 
coagulation cascade, namely the formation of the thrombin. In turn, thrombin cleaves-off fibrinogen 
fibrinopeptides provoking fibrin formation and self-assembling to fibrin clot. It has been suggested that 
compounds which selectively inhibit Factor Xa may be useful as in vitro diagnostic agents, or can be used 
as therapeutic agent being administrated in certain thrombotic disorders. 
Selective Factor Xa inhibitors decrease risk of bleedings and improved safety/efficiency ratio at the 
preclinical stages of drug development, in comparison to thrombin inhibitors. The Factor Xa inhibitors 
are classified as direct and indirect inhibitors depending on the mechanism of action. Direct inhibitors 
interact directly with the Factor Xa active site and block it. These inhibitors bind efficiently to clot-bound 
and prothrombinase-associated forms of Factor Xa, unlike the indirect inhibitors. The action mode of 
indirect inhibitors is based on Factor Xa inactivation by antithrombin [2, P. 671-698].  
Methods. The amidolytic activity of Factor Xa was determined by measuring the amount of p-NA 
released upon hydrolysis of chromogenic substrate. The hydrolysis rate of chromogenic substrate was 
evaluated by measuring the absorbance at 405 nm at 37 °C at 5 min incubation in Tissue CulturePlate 96-
Well Flat Bottom (Sterile) with a microplate reader (Multiscan EX). The reaction mixture in 0.05 M Tris-
HCl buffer (pH 7.45) with 0.13 M NaCl and 10
-3
 M CaCl2 with total volume 0.25 ml contained: for blood 
plasma: referent blood plasma – 0.04 ml/ml; Factor Xa activator – 0.02 ml of 1 mg/ml solution – snake 
venom Vipera russelli (RVV) [3, p. 211-217]; inhibitor – 5·10-6 M; S2765 (Z-D-Arg-Gly-Arg-pNA 
2HCl) – 0.16 mM; for purified Factor Xa: purified bovine Factor Xa (Hemolab Heparichrom) – 0.27 
nkat/ml; inhibitor 5·10-6 M, S2765 (Z-D-Arg-Gly-Arg-pNA 2HCl) – 0.16 mM. 
The rate of the reaction was measured as the change of absorbance per minute. 
For Ki calculation the equation of competitive type inhibition was used: 
Ki = [I]/(Kp/Km – 1), where Kp and Km – the effective Michaelis constants calculated from 
Lineweaver-Burk plot at 4 presence and absence of the inhibitors respectively. 
Results. All the selected 1400 compounds have been subjected to test with use of RVV-test modified 
assay (RVVT). We have monitored inhibition activity of the compounds at 5 minutes. We observed the 
exponential-like regression of the compounds number of along the potency increase (Fig. 1). To assess 
activity of the most active compounds we selected 59 compounds that have exhibited activity more than 
70 % and subjected them to further biological screening on purified Factor Xa. The screening was 
performed with a 5 μM inhibitor concentration. Most of the selected compounds possess activity ranging 
from 40 % to 60 %. We selected only 17 compounds that inhibited the activity of Factor Xa on 60-100 % 
(Fig.). 
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Fig. – Activity distribution of the factor Xa targeted library. Activity distribution of the 1400 compounds 
subjected to modified RVVT assay at 50 µM inhibitor concentration. Exponential regression is observed. 
 
All samples were tested in 2 model systems as it is described in Materials and methods. The data 
analysis indicated highest inhibitory activity of two components. The Lineweaver-Burk plot was built 
according to experimental data to confirm inhibition type and calculate the inhibition constant for the 
most active inhibitor. The intersection of the curves on the Y-axis suggested the competitive character of 
inhibition (Кi=13,9·10
-6
 M). This value of the inhibition constant demonstrated the high affinity of the 
inhibitor to the enzyme. 
Conclusions. We used virtual screening to select from the stock virtually generated library those 
compounds which effectively inhibited Factor Xa activity. The composed set consisted of 1400 
compounds that all were subjected to RVVT in vitro screening. Two compounds with prominent 
inhibitory activity towards Factor Xa were selected. Their scaffold easily allows us to synthesize water 
soluble derivatives without any lose in other properties. 
Acknowledgement. Publication is based on the research provided by the grant support of the State 
Fund For Fundamental Research (project N 76/69-2017) 
 
Literature 
1. Kalafatis M. The regulation of clotting factors / M. Kalafatis, J.O. Egan, C. van Veer, K.M. 
Cawthern, K.G. Mann // Crit Rev Eukaryot Gene Expr. 1997; 7: 241-80. 
2. Patel, N.R. Contemporary developments in the discovery of selective factor Xa inhibitors: A review 
/ N.R. Patel, D.V.Patel, P.R. Murumkar, M.R. Yadav // Eur J Med Chem. – 2016. – Vol. 121. – P. 671-
698.  
3. Marsh N.A. Diagnostic uses of snake venom / N.A. Marsh // Haemostasis. 2001. – Vol. 3-6. – P. 
211-217. 
 
УДК 577.11+577.112.6+615.46+615.456 
 
ПОЛУЧЕНИЕ И СВОЙСТВА КОМПОЗИТНЫХ НАНОВОЛОКОН НА ОСНОВЕ 
ПУЛЛУЛАНА И НАНОСТРУКТУР БАВ С ЦИКЛОДЕКСТРИНАМИ 
 
1КАПУСТИН Максим Александрович, науч. сотрудник 
1ЧУБАРОВА Анна Сергеевна, к.б.н., ст. науч. сотрудник 
1КУРЧЕНКО Владимир Петрович, к.б.н., доцент, зав. НИЛ 
2ЛОДЫГИН Алексей Дмитриевич, д.т.н., доцент, зам. директора института живых  
систем по научной работе, зав. кафедрой прикладной биотехнологии 
2РЖЕПАКОВСКИЙ Игорь Владимирович, к.б.н., доцент, вед. науч. сотрудник 
1Белорусский государственный университет 
2Северо-Кавказский федеральный университет 
 
Введение. Технология электроспиннинга может быть использована для получения разнообраз-
ных биосовместимых материалов, целесообразных к применению в медицине в процессе лечения 
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